secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021868
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics Q3 net loss $84.2M ($0.76/sh); RLY-4008 88% ORR in FGFR2-fusion CCA
--------------------------------------------------------------------------------

- Net loss $84.2M vs $60.8M YoY; R&D expenses rose to $66.9M from $45.0M.
- Cash and investments $1.1B as of Sep 30, 2022; sufficient to fund operations into 2025.
- RLY-4008 interim data: 88% ORR at pivotal dose in FGFRi-naive FGFR2-fusion cholangiocarcinoma (n=17).
- Raised $300M gross proceeds in follow-on public offering during Q3.
- RLY-2608 (PI3Kα inhibitor) continues enrolling in single-agent and combination cohorts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017022021868/0000950170-22-021868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017022021868/rlay-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer